SARS-CoV-2 peptides/epitopes for specific and sensitive diagnosis  

作　　者：He-Wei Jiang Yang Li Sheng-Ce Tao 

机构地区：[1]Shanghai Center for Systems Biomedicine,Key Laboratory of Systems Biomedicine(Ministry of Education),Shanghai Jiao Tong University,Shanghai 200240,China.

出　　处：《Cellular & Molecular Immunology》2023年第5期540-542,共3页中国免疫学杂志（英文版）

基　　金：the National Key Research and Development Program of China Grant(No.2020YFE0202200);the National Natural Science Foundation of China(Nos.31900112 and 31970130).

摘　　要：The COVID-19 pandemic,caused by SARS-CoV-2,has presented an unprecedented challenge to global public health.The rapid,reliable,and affordable diagnosis of COVID-19 is essential for controlling the spread of the acute disease[1].The nucleic acid test(NAT)is the gold standard for diagnosing COVID-19 due to its high sensitivity and accuracy[1].Although NAT yields clinically actionable information,false-negative results often occur,especially when sample collection is not performed appropriately[2].To complement NAT,serological testing is essential for the rapid detection and monitoring of mild or asymptomatic infections[1].Serological tests provide valuable information for improving diagnosis,including the estimation of population exposure,disease severity,and clinical outcomes[1].

关 键 词：DIAGNOSIS app false 

分 类 号：R392[医药卫生—免疫学]